Navigation Links
NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
Date:10/18/2010

i>.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements about NeurogesX' plans to submit a supplemental NDA to the FDA and the timing of such submission; expected data to be included in such submission; additional market reach of expanding the Qutenza label to include treatment of pain associated with HIV-AN and the ability to use the U.S. sales force and other relationships to facilitate commercialization of Qutenza in the potential new indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Sara Pellegrino (investor
'/>"/>


SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at J.P. Morgan Health Care Conference
2. NeurogesX to Present at Piper Jaffray Health Care Conference
3. NeurogesX Reports Third Quarter 2009 Results
4. NeurogesX to Present at Two November Conferences
5. NeurogesX to Present at UBS Global Life Sciences Conference
6. NeurogesX to Present at Upcoming Fall Conferences
7. NeurogesX Appoints New Board Director and Audit Committee Chairman
8. NeurogesX Reports Second Quarter 2009 Results
9. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
10. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
11. NeurogesX Added to Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... increasing global demand for health ... economics and market access support, BOSTON, Oct. ... Adam Barak as Vice President., Mr. Barak brings 16 ... pricing and reimbursement strategies,for drugs, medical devices, and diagnostics in ...
... Also Announces Completion of Enrollment in U.S. Phase ... Hepatitis C,Genotype 1, TAMPA, Fla., Oct. 28 ... announced the presentation of studies,of nitazoxanide at the ... the Study of Liver Diseases (AASLD), also known ...
... - Laureate To Manufacture Tolera,s Monoclonal Antibody ... 28 Laureate Pharma, Inc., a,full-service biopharmaceutical ... it has entered into a cGMP contract ... company that,develops and offers targeted therapies and ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2
(Date:8/22/2014)... presented at the 29th Annual International Papillomavirus Conference ... Therapeutics Inc. combats three types of human papillomavirus, ... all cervical cancer. , When tested in several ... of HPV-16, HPV-18 and HPV-11 cells, according to ... who presented the findings at the Seattle conference. ...
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
(Date:8/22/2014)... consumers will finally be able to purchase fuel cell ... zero-emissions vehicles, most of the cars will run on ... contributes to global warming. , Now scientists at Stanford ... an ordinary AAA battery to produce hydrogen by water ... two electrodes that split liquid water into hydrogen and ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... to provide a detailed picture of how and when ... in animals, including humans. The evolutionary origins of ... of phylogenetic relationships among the earliest opsin-possessing animals. ... and colleagues at NUI Maynooth performed a computational analysis ...
... , Inc. (OTCBB: BLFS), a leading developer, manufacturer and ... and cryopreservation freeze media for cells and ... announced the Company,s novel biopreservation technology is being used ... it the leading choice in the emerging, high growth ...
... you fitter than ever mentally fit. In a ... of high-intensity interval training. At the end, their cognitive functions ... had improved significantly, says Dr. Martin Juneau, director of ... to people who exercise, they say they feel sharper. Now ...
Cached Biology News:BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 2BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 3BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 4Exercise is smart for your heart - and makes you smarter 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: